Empowered Diagnostics is recalling two Covid-19 tests, CovClear COVID-19 Rapid Antigen Test and ImmunoPass COVID-19 Neutralizing Antibody Rapid Test, as they have been distributed with labels incorrectly indicating that they are US Food and Drug Administration (FDA) authorised.

The FDA has identified the recall of the two products as Class 1, the most serious recall type, as they could potentially lead to a higher risk of false results.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It noted that false results could lead to serious adverse health consequences or death.

A delayed diagnosis of the SARS-CoV-2 virus, leading to further spread of the virus, could be expected due to a false-negative test result.

The CovClear COVID-19 Rapid Antigen Test is designed to detect SARS-CoV-2 antigens from a nasal swab sample.

Meanwhile, the ImmunoPass COVID-19 Neutralizing Antibody Rapid Test uses a fingerstick blood sample to detect antibodies produced by the immune system in response to the SARS-CoV-2 virus.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Empowered Diagnostics sent a Voluntary Recall e-mail to its distributors and customers, instructing them to stop using and distributing all the affected tests, on 20 December last year.

The FDA is suggesting that test users and caregivers talk to their healthcare provider if they have concerns about their test results after testing with either of the Empowered Diagnostics Covid-19 tests.

Healthcare providers and testing programme organisers are required to consider retesting patients using a SARS-CoV-2 diagnostic test authorised by the FDA if they suspect an inaccurate result following the use of a CovClear COVID-19 Rapid Antigen Test.

However, if testing was performed with CovClear more than two weeks ago and there is no reason to suspect a current infection, no retesting is needed.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact